Table 3.

Kinetic results of samples binding to PD-L1 and VEGF with a 1:1 binding model.

Ligand	Enhancement	Analyte	Kinetics Chi2 (RU2)	Ka (1/Ms)	Kd (1/s)	KD (M)
HB0025	Buffer	VEGF165	4.30E-01	1.44E+08	6.81E-04	4.72E-12
	PD-L1	VEGF165	2.31E-01	1.48E+08	4.41E-04	2.98E-12
	Buffer	PD-L1	1.18E-01	2.90E+05	5.10E-04	1.76E-09
	VEGF165	PD-L1	6.02E-02	2.00E+05	3.95E-04	1.98E-09
HB002.1T	\	VEGF165	2.01E-01	4.54E+07	5.03E-05	1.11E-12
HB0023	\	PD-L1	9.77E-02	2.34E+05	5.25E-04	2.24E-09
Bevacizumab	\	VEGF165	1.91E-02	1.41E+06	6.17E-04	4.39E-10
Atezolizumab	\	PD-L1	9.22E-02	1.04E+06	5.01E-04	4.82E-10